Suppr超能文献

利用红细胞抗原基因分型和镰状细胞病患者的血清学表型对患者进行同种免疫风险分层。

Utilising red cell antigen genotyping and serological phenotyping in sickle cell disease patients to risk-stratify patients for alloimmunisation risk.

机构信息

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Medical Services and Hospital Relations, Canadian Blood Services, Vancouver, British Columbia, Canada.

出版信息

Transfus Med. 2020 Aug;30(4):263-274. doi: 10.1111/tme.12685. Epub 2020 May 20.

Abstract

BACKGROUND

Alloimmunisation and haemolytic transfusion reactions (HTRs) can occur in patients with sickle cell disease (SCD) despite providing phenotype-matched red blood cell (RBC) transfusions. Variant RBC antigen gene alleles/polymorphisms can lead to discrepancies in serological phenotyping. We evaluated differences between RBC antigen genotyping and phenotyping methods and retrospectively assessed if partial antigen expression may lead to increased risk of alloimmunisation and HTRs in SCD patients at a tertiary centre in Canada.

METHODS

RBC antigen phenotyping and genotyping were performed by a reference laboratory on consenting SCD patients. Patient demographic, clinical and transfusion-related data were obtained from a local transfusion registry and chart review after research ethics board approval.

RESULTS

A total of 106 SCD patients were enrolled, and 91% (n = 96) showed additional clinically relevant genotyping information when compared to serological phenotyping alone. FY02N.01 (FYB GATA-1) (n = 95; 90%) and RH variant alleles (n = 52, 49%; majority accompanied by FY*02N.01) were common, the latter with putative partial antigen expression in 25 patients. Variability in genotype-phenotype antigen prediction occurred mostly in the Rh system, notably with the e antigen (kappa: 0.17). Fifteen (14.2%) patients had a history of alloimmunisation, with five having HTR documented; no differences in clinical outcomes were found in patients with partial antigen expression. Genotype/extended-phenotype matching strategies may have prevented alloimmunisation events.

CONCLUSION

We show a high frequency of variant alleles/polymorphisms in the SCD population, where genotyping may complement serological phenotyping. Genotyping SCD patients before transfusion may prevent alloimmunisation and HTRs, and knowledge of the FY*02N.01 variant allele increases feasibility of finding compatible blood.

摘要

背景

尽管为镰状细胞病(SCD)患者提供了表型匹配的红细胞(RBC)输注,但仍可能发生同种免疫和溶血性输血反应(HTR)。变体 RBC 抗原基因等位基因/多态性可导致血清表型检测出现差异。我们评估了 RBC 抗原基因分型和表型检测方法之间的差异,并回顾性评估了在加拿大一家三级中心的 SCD 患者中,部分抗原表达是否会导致更高的同种免疫和 HTR 风险。

方法

同意的 SCD 患者的 RBC 抗原表型和基因分型由参考实验室进行。患者人口统计学、临床和输血相关数据是在获得研究伦理委员会批准后,从当地输血登记处和图表审查中获得的。

结果

共纳入 106 例 SCD 患者,与单独的血清学表型相比,91%(n=96)的患者显示出额外的临床相关基因分型信息。FY02N.01(FYB GATA-1)(n=95;90%)和 RH 变体等位基因(n=52,49%;大多数伴有 FY*02N.01)很常见,后者在 25 名患者中具有部分抗原表达。基因型-表型抗原预测的基因型多样性主要发生在 Rh 系统,尤其是 e 抗原(kappa:0.17)。15 名(14.2%)患者有同种免疫史,其中 5 名患者有 HTR 记录;在具有部分抗原表达的患者中,临床结局没有差异。基因型/扩展表型匹配策略可能预防了同种免疫事件。

结论

我们发现 SCD 人群中变体等位基因/多态性的频率很高,其中基因分型可能补充血清学表型检测。在输血前对 SCD 患者进行基因分型可能会预防同种免疫和 HTR,并增加发现相容血液的 FY*02N.01 变体等位基因的可行性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验